Over the past several years, the gynecologic oncology program at RUSH has seen tremendous growth; it’s one of the highest-volume programs in the Chicago area. Gynecologic oncologists from RUSH University System for Health also bring academic medicine into the community, providing patients throughout the Chicago area with the best possible care and access to clinical trials.

**Novel Treatments**

**Minimally invasive surgery.** The experienced team of gynecologic oncologists at RUSH has been performing a high volume of cancer surgeries robotically for many years, while focusing on continuous quality improvement, growth and refinement.

We have expertise in novel surgical techniques, using the da Vinci Surgical System, including sentinel lymph node dissection for endometrial cancer.

**Precision medicine.** The gynecologic cancer program partners with Tempus — a biotechnology company that collects, stores and analyzes genetic data, clinical information and tissue samples — to provide advanced care to patients who have gynecologic malignancies by using data-driven precision medicine.

At RUSH, all patients who have advanced-staged or recurrent gynecologic cancers are offered Tempus testing coupled with tissue banking at the RUSH biorepository.

**Immunotherapies.** Working with Tempus, our experts have seen that immunotherapies can be beneficial for treating recurrent gynecologic cancers. They do genetic sequencing and tissue testing for patients, which shows each patient’s individual sensitivities to different treatments.

**Clinical Trials**

RUSH also offers clinical trials for gynecologic malignancies through Gynecologic Oncology Group (GOG) Partners and NRG Oncology, both of which are sponsored by the National Cancer Institute. The team evaluates all patients for eligibility and offers patients a trial during their care if appropriate.

These are some of RUSH’s current clinical trials for gynecologic cancers:

- **NRG GY005**
  Cediranib Maleate and Olaparib or Standard Chemotherapy in Treating Patients With Recurrent Platinum-Resistant or Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

- **NRG-GY006**
  A Randomized Phase II Trial of Radiation Therapy and Cisplatin Alone or in Combination With Intravenous Triapine in Women with Newly Diagnosed Bulky Stage IB2, Stage II, IIIB, or IVA Cancer of the Uterine Cervix or Stage II-IVA Vaginal Cancer.

- **GOG PARTNERS – GOG 3018 OVAL STUDY**
  A Study of VB-111 With Paclitaxel vs Paclitaxel for Treatment of Recurrent Platinum-Resistant Ovarian Cancer (OVAL)

- **GOG 3032 – TESARO MOONSTONE TRIAL**
  A Phase 2 Open-Label, Single-Arm Study to Evaluate the Efficacy and Safety of the Combination of Niraparib and TSR-042 in Patients With Platinum-Resistant Ovarian Cancer
Meet Our Team

Gynecologic Oncologists

Amina Ahmed, MD, MS
Summer Dewdney, MD
Andras Ladanyi, MD, PhD

Advanced Practice Providers

Natalie Colson, PA-C
Margaret Dolan, MMS, PA-C
Maria Jacob, PA-C

Pathologist

Lei Yan, MD

Medical Oncologist

Lydia Usha, MD

Radiation Oncologist

Sarah Dooley, MD
Ken Tatebe, MD

Locations

RUSH University Medical Center
Joan and Paul Rubschlager Building
1520 W. Harrison St.
Chicago, IL 60612

RUSH Cancer Care in Oak Park
RUSH Medical Office Building,
RUSH Oak Park Hospital
610 S. Maple Ave.,
Suite 2100
Oak Park, IL 60304

RUSH Copley Cancer Center
2000 Ogden Ave.
Aurora, IL 60504

Riverside Cancer Institute
200 Riverside Drive
Bourbonnais, IL 60941

St. James Hospital and Health Centers
Comprehensive Cancer Institute
3900 W 203 St.
Olympia Fields, IL 60461

Midwest Center for Women’s HealthCare
210 McHenry Road
Buffalo Grove, IL 60089

Excellence is just the beginning.